CAS: 105816-06-6; N-[[cis-4-(1-Methylethyl)Cyclohexyl]Carbonyl]-D-Phenylalanine
该化合物是糖尿病治疗中使用的一种短效胰岛素异丙酸制剂,合成甲状腺素的中间或副产品.该化合物对于分析和质量控制,确保活性药物成分的纯度和功效至关重要.其明确界定的结构和高化学稳定性使它适合用作HPLC,LC-MS和其他色谱方法的参考标准.它通过促进精确的杂质特征分析,帮助遵守严格的监管要求(例如ICH准则)并支持稳健的制药发展.高纯度的药物供应提高了研究的准确性和制造的一致性.
- 英文名称N-[[cis-4-(1-Methylethyl)Cyclohexyl]Carbonyl]-D-Phenylalanine
- 中文名称N-[[顺式-4-(1-甲基乙基)环己基]羰基]-D-苯丙氨酸
- IUPAC名称((1s,4S)-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine
- 其它别名D-Phenylalanine, N-[[4-(1-Methylethyl)Cyclohexyl]Carbonyl]-, Cis-; D-Phenylalanine, N-[[cis-4-(1-Methylethyl)Cyclohexyl]Carbonyl]- (9Ci); N-(Cis-4-Isopropylcyclohexanecarbonyl)-D-Phenylalanine; Nateglinide Related Compound C; Nateglinide Related Compound C (5 Mg) (N-(Cis-4-Isopropylcyclohexanecarbonyl)-D-Phenylalanine); N-[[cis-4-(1-Methylethyl)Cyclohexyl]Carbonyl]-D-Phenylalanine (Nateglinide Impurity); N-[(Cis-4-Isopropylcyclohexyl)Carbonyl]-D-Phenylalanine; N-[[cis-4-(1-Methylethyl)Cyclohexyl]Carbonyl]-D-Phenylalanine
- CAS编号105816-06-6
- MFCD编号:MFCD21606974
- 分子式:C19H27NO3分子量:317.43
- 产品CID: 99126
- 产品分类有机原料→分子砌块→芳环类化合物→苯类化合物
相似化合物
105816-05-5 187728-85-4 105746-47-2MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2905121000-正丙醇
2905399099-其他二元醇
2905499000-其他多元醇
2905590090-其他无环醇的卤化、磺化等衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
[参考文献]: Lauretta Maggi, Et Al. I. Technological Approaches To Improve The Dissolution Behavior Of Nateglinide, A Lipophilic Insoluble Drug: Nanoparticles And Co-Mixing. Int J Pharm. 2013 Sep 15;454(1):562-7.[参考文献]: Lauretta Maggi, Et Al. Ii. Technological Approaches To Improve The Dissolution Behavior Of Nateglinide, A Lipophilic Insoluble Drug: Co-Milling. Int J Pharm. 2013 Sep 15;454(1):568-72.
[参考文献]: Pratik Upadhyay, Et Al. Estimating Relative Stability Of Polymorphs By Generation Of Configurational Free Energy Phase Diagram. J Pharm Sci. 2012 May;101(5):1843-51.
[参考文献]: Roberto Latini, Et Al. Incidence Of Atrial Fibrillation In A Population With Impaired Glucose Tolerance: The Contribution Of Glucose Metabolism And Other Risk Factors. A Post Hoc Analysis Of The Nateglinide And Valsartan In Impaired Glucose Tolerance Outcomes Research Trial. Am Heart J. 2013 Nov;166(5):935-40.E1.
[参考文献]: Sajid Bashir, Et Al. Formulation And In Vitro Evaluation Of Nateglinide Microspheres Using Hpmc And Carbopol-940 Polymers By Ionic Gelation Method. Pak J Pharm Sci. 2013 Nov;26(6):1229-35.
📝 需求与反馈
尽可能描述清楚需求与问题信息
